Health Enhancement Products, Inc. Schedules Investor Conference Call at 11:00AM EST on Tuesday, January 17, 2012

BLOOMFIELD HILLS, MI--(Marketwire - Jan 10, 2012) - Arizona-based algae producer Health Enhancement Products (OTCBB: HEPI) has scheduled a conference call open to investors and other interested parties at 11:00AM Eastern Standard Time on Tuesday, January 17, 2012. The call will be conducted by incoming CEO Andrew Dahl. The format for the call is basic -- a prepared statement by HEPI President & CEO Andrew Dahl, followed by a 20-minute Q&A session when Mr. Dahl takes questions from callers.

"As new management steps in, we want to schedule regular communication with shareholders and the investment community at large," states Dahl. "In addition to quarterly conference calls and press releases for breaking news, we are also preparing to revamp the corporate website and re-focus its content."

Topics for the conference call will include statements regarding recent changes to the board, the move of administrative functions from Arizona to Michigan, and updates to the progress of scientific research at Battelle, along with new strategies for future product applications.

Callers will be encouraged to submit questions for the Q&A session that follows prepared remarks.

11:00AM Eastern Standard Time, January 17 2012.

Participant Dial-In Numbers:

TOLL-FREE 1-877-941-4774
TOLL/INTERNATIONAL 1-480-629-9760

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of natural products derived from algae cultures for use as dietary supplements and food ingredients. These natural products are extracted from living algae grown in purified water.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.